Metabolic Disorders
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Travere Looks Ahead To Phase III In Homocystinuria
The latest data from a Phase I/II study shows that pegtibatinase can yield a rapid, sustained reduction in homocysteine, the protein behind the underlying cause of the rare disease.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: novel BMS drug shows promise in IPF; Novo’s oral semaglutide compares well with injectable in weight loss; Teva looks to innovative brands to return to growth; US setback for Intercept’s NASH drug; and India’s improving environment for clinical trials.
Pfizer Will Struggle To Catch Novo Nordisk With Oral Obesity Treatments
Novo Nordisk reasserted its dominance in the GLP-1 agonist field this week, while Pfizer must hope that one of its two shots on goal is a success.
Novo’s Oral Semaglutide Delivers Similar Weight Loss To Wegovy In Phase III
A 50mg dose of oral semaglutide showed similar weight loss to the weekly injectable version that Novo already markets as Wegovy.
Novo Nordisk’s Obesity Drug Activities Break UK Rules Again
The company has been found in breach of the UK code once again for its work with pharmacists, although this time Novo Nordisk has escaped the heaviest censure.
Cystinosis Results Help Rebuild Confidence In AvroBio’s Gene Therapy
The lentiviral gene therapy company is still trading below cash, but the cystinosis results add extra momentum to its comeback.
Poxel Looks To More Twymeeg Partnerships In Asia To Pay Off Debt
The French firm’s antidiabetic drug has enjoyed some traction in the Japanese market following the end of launch year restrictions, raising hopes that other Asian partnerships could help improve its financial position.
Belgium's Sequana Sits At Junction Between Pharma And Medtech
The company’s dual drug-device development pipeline is progressing well, especially its direct sodium removal therapy for congestive heart failure.
Boehringer/Zealand’s Obesity Asset Succeeds In Phase II But Competition Is Fierce
The partners’ dual GLP-1/GCGR agonist has achieved up to 14.9% weight loss in obese and overweight adults in a mid-stage trial but rival products Wegovy and Mounjaro will likely dominate the space according to analysts.
Wegovy Demand Busts Through Novo Nordisk’s Expanded Capacity
Novo Nordisk said it would temporarily reduce production of the lower starting dose of Wegovy even as a second contract manufacturer has come online in April.
Lilly’s Mounjaro Shows Strong Sales And Data As Firm Eyes Obesity Market
Excluding COVID-19 antibodies, the company said revenues for the quarter increased by 10% while volume increased by 18%, and sales of Mounjaro came in stronger than analysts anticipated.
Sanofi Sees Dupixent As Just The Start Of COPD Transformation
Dupixent’s surprise success in COPD is welcome news, but it remains uncertain whether regulators will demand a second study readout before filing. In the meantime, Sanofi highlighted another promising late-stage candidate for the hard-to-treat disease during its Q1 results.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.